FGEN - FibroGen, Inc.
| Previous Close | 43.53 |
| Open | 43.43 |
| Bid | 40.69 x 800 |
| Ask | 62.66 x 1400 |
| Day's Range | 41.57 - 43.88 |
| 52 Week Range | 33.51 - 61.95 |
| Volume | 520,837 |
| Avg. Volume | 630,712 |
| Market Cap | 3.626B |
| Beta (3Y Monthly) | 2.13 |
| PE Ratio (TTM) | 74.63 |
| EPS (TTM) | 0.56 |
| Earnings Date | Nov 6, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 64.00 |
- GuruFocus.com
Fibrogen Inc (FGEN) CEO Thomas B Neff Sold $1.8 million of Shares
CEO of Fibrogen Inc (30-Year Financial, Insider Trades) Thomas B Neff (insider trades) sold 39,636 shares of FGEN on 08/22/2019 at an average price of $44.33 a share. Continue reading...
- Zacks
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
AstraZeneca's (AZN) roxadustat gets a second marketing approval in China for treating anaemia caused by chronic kidney disease in non-dialysis-dependent patients.
- Benzinga
The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 21) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arrowhead ...
- GlobeNewswire
Roxadustat Approved in China for Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis
FibroGen, Inc. (FGEN) today announced that the National Medical Products Administration (NMPA) in China has approved expansion of the marketing authorization of roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with anemia caused by chronic kidney disease (CKD) to include treatment in CKD patients who are not dialysis-dependent (NDD). Marketing authorization for roxadustat for the treatment of anemia associated with CKD in patients who are dialysis-dependent (DD) was granted by the NMPA in December of 2018. Anemia commonly develops in the presence of CKD, and is associated with cardiovascular disease, hospitalization, increased mortality risk, cognitive impairment, and reduced quality of life.1 NDD-CKD patients in China include CKD Stage 3, Stage 4, and Stage 5 patients who are not eligible for dialysis, as well as a sizeable population of end-stage renal disease patients who are eligible for, but who are not receiving, dialysis.
- Zacks
Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta
The FDA approves Nabriva's (NBRV) new drug application for both intravenous and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia.
- Zacks
Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4
Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.
- Thomson Reuters StreetEvents
Edited Transcript of FGEN earnings conference call or presentation 8-Aug-19 9:00pm GMT
Q2 2019 FibroGen Inc Earnings Call
- Zacks
Tilray (TLRY) Catches Eye: Stock Jumps 8.4%
Tilray (TLRY) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
- Simply Wall St.
FibroGen (NASDAQ:FGEN) Has A Pretty Healthy Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Motley FoolFibroGen Inc (FGEN) Q2 2019 Earnings Call Transcript
FGEN earnings call for the period ending June 30, 2019.
- Zacks
FibroGen (FGEN) Q2 Earnings and Revenues Top Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of 357.14% and 492.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
CORRECTION - FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019
SAN FRANCISCO, Aug. 01, 2019 -- In a release issued under the same headline earlier today by FibroGen, Inc (NASDAQ: FGEN) we are advised by the company the “Live (U.S./Canada)”.
- GlobeNewswire
FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019
SAN FRANCISCO, Aug. 01, 2019 -- FibroGen, Inc. (NASDAQ: FGEN), today announced that it will report second quarter 2019 financial results on Thursday, August 8, 2019 after.
- Zacks
Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GuruFocus.com
Fibrogen Inc (FGEN) CEO Thomas B Neff Sold $1.9 million of Shares
CEO of Fibrogen Inc (30-Year Financial, Insider Trades) Thomas B Neff (insider trades) sold 39,636 shares of FGEN on 07/25/2019 at an average price of $46.74 a share. Continue reading...
- GlobeNewswire
Roxadustat China Phase 3 Trial for Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine (NEJM)
FibroGen, Inc. (FGEN) today announced publication of results from the Phase 3 trial of the efficacy and safety of roxadustat treatment compared to placebo for anemia in non-dialysis patients (NDD) with chronic kidney disease (CKD) in the People’s Republic of China (China) in the New England Journal of Medicine (NEJM)1. In this study, roxadustat met its primary efficacy endpoint for anemia correction by achieving a statistically significant increase in mean hemoglobin level from baseline to hemoglobin level averaged over Weeks 7 through 9.
- GlobeNewswire
The New England Journal of Medicine (NEJM) Publishes Roxadustat China Phase 3 Results for the Treatment of Anemia in Chronic Kidney Disease Patients Receiving Dialysis
-- One of Two Concurrent Publications of Roxadustat China Phase 3 Results in The New England Journal of Medicine -- SAN FRANCISCO, July 24, 2019 -- FibroGen, Inc. (NASDAQ:.
- GlobeNewswire
FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
FibroGen, Inc. (FGEN), today announced dosing of the first patient in the ZEPHYRUS Phase 3 clinical study of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF). “There is an urgent need for new treatments that will help IPF patients, who have limited or no treatment options,” said Luca Richeldi, M.D., Ph.D., Head of the Division of Pulmonary Medicine at Agostino Gemelli University Hospital of the Catholic University of the Sacred Heart in Rome, Italy.
- Simply Wall St.
Shareholders Are Thrilled That The FibroGen (NASDAQ:FGEN) Share Price Increased 165%
FibroGen, Inc. (NASDAQ:FGEN) shareholders might be concerned after seeing the share price drop 15% in the last...
- GlobeNewswire
FibroGen to Present Interim Phase 2 Data on Pamrevlumab in Subjects with Duchenne Muscular Dystrophy at the Parent Project Muscular Dystrophy 2019 Annual Conference
SAN FRANCISCO, June 28, 2019 -- FibroGen, Inc. (NASDAQ: FGEN), today announced that the company will present interim data on their open-label, single-arm Phase 2 trial.
- Markit
See what the IHS Markit Score report has to say about FibroGen Inc.
FibroGen Inc NASDAQ/NGS:FGENView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for FGEN with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 11. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding FGEN are favorable, with net inflows of $2.57 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Insider Monkey
Here’s What Hedge Funds Think About FibroGen Inc (FGEN)
Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by nearly 9 percentage points since the end of the third quarter of 2018 as investors worried over the possible ramifications of rising interest rates and escalation of the trade war with China. The hedge funds and institutional investors we track typically invest more […]
- Simply Wall St.
Can We See Significant Institutional Ownership On The FibroGen, Inc. (NASDAQ:FGEN) Share Register?
Every investor in FibroGen, Inc. (NASDAQ:FGEN) should be aware of the most powerful shareholder groups. Generally...
